Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
CABO+NIVL; CABO(MNT)
Cancer Type
Genitourinary,
Renal cell Kidney
Intent
Palliative
Regimen Category
Evidence-informed
Funding Program
New Drug Funding Program
Nivolumab - In Combination with Cabozantinib for First Line Advanced or Metastatic Renal Cell Carcinoma
Exceptional Access Program
cabozantinib – For the first-line treatment of adult patients with advanced or metastatic renal cell carcinoma, in combination with nivolumab, based on criteria
Drugs in Regimen
Regimen Monograph
Nov 2024
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: August 12, 2026
